Search 

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders

ImmunoBiochem is an immuno-oncology biopharmaceutical company that has developed a disruptive approach to targeting unique proteins amplified in cancer secretomes. These targets are secreted from cancer cells and accumulate in tumors, but not in normal tissues, and are constantly recycled in the tumor microenvironment. This novel approach enables the selective and efficacious delivery of immunomodulatory and chemotherapeutic payloads into relevant subsets of cells within the tumor microenvironment, including tumor cells, immune cells and tumor-supporting stroma.
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

CRO Preclinical
In vivo efficacy evaluation in oncology

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.

Leading global PE